Anti-Actin IgA Antibodies Identify Celiac Disease Patients with a Marsh 3 Intestinal Damage among Subjects with Moderate Anti-TG2 Levels
A new diagnostic tool (algorithm-1) for coeliac disease (CD) permitting the diagnosis without performing the duodenal biopsy has been recently proposed by the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). It combines symptoms associated with CD, high anti-tra...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2013-01-01
|
Series: | BioMed Research International |
Online Access: | http://dx.doi.org/10.1155/2013/630463 |
id |
doaj-c9e78bf6b2b94f92bd59b8360a4d7b1b |
---|---|
record_format |
Article |
spelling |
doaj-c9e78bf6b2b94f92bd59b8360a4d7b1b2020-11-25T01:06:51ZengHindawi LimitedBioMed Research International2314-61332314-61412013-01-01201310.1155/2013/630463630463Anti-Actin IgA Antibodies Identify Celiac Disease Patients with a Marsh 3 Intestinal Damage among Subjects with Moderate Anti-TG2 LevelsEnrico Schirru0Fabrice Danjou1Lucia Cicotto2Rossano Rossino3Maria Doloretta Macis4Rosanna Lampis5Rita-Désirée Jores6Mauro Congia7Department of Public Health, University of Cagliari, Cittadella Universitaria, Monserrato, 09045 Cagliari, ItalyDepartment of Public Health, University of Cagliari, Cittadella Universitaria, Monserrato, 09045 Cagliari, ItalyGastroenterology Unit, Microcitemico Hospital, ASL8 Cagliari, Via Jenner, 09121 Cagliari, ItalyDepartment of Public Health, University of Cagliari, Cittadella Universitaria, Monserrato, 09045 Cagliari, ItalyDepartment of Public Health, University of Cagliari, Cittadella Universitaria, Monserrato, 09045 Cagliari, ItalyDepartment of Public Health, University of Cagliari, Cittadella Universitaria, Monserrato, 09045 Cagliari, ItalyDepartment of Public Health, University of Cagliari, Cittadella Universitaria, Monserrato, 09045 Cagliari, ItalyGastroenterology Unit, Microcitemico Hospital, ASL8 Cagliari, Via Jenner, 09121 Cagliari, ItalyA new diagnostic tool (algorithm-1) for coeliac disease (CD) permitting the diagnosis without performing the duodenal biopsy has been recently proposed by the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). It combines symptoms associated with CD, high anti-transglutaminase type 2 antibody (anti-TG2) levels, anti-endomysium-IgA antibodies (EMA), and at-risk HLA. Our aims were (i) to evaluate retrospectively in 227 individuals (149 CD patients and 78 controls) the algorithm-1, (ii) to reduce the number of duodenal biopsies among CD patients for whom algorithm-1 is not applicable through the addition of antiactin IgA antibodies (AAA-IgA), and (iii) to evaluate prospectively algorithm-1 and AAA-IgA in 50 patients with suspected CD. Algorithm-1 identified 70 out of 149 CD patients with Marsh 3 lesions. Adding AAA-IgA to the remaining patients with anti-TG2 levels comprised between 4 and 10 times upper limit of normal (ULN) allowed the detection of further 20 patients with a Marsh 3 damage. In our prospective study, algorithm-1 identified 23 out of 50 patients, whilst further 7 were recognized adding AAA-IgA. We confirm that algorithm-1 may avoid the duodenal biopsy in many CD patients and underscores the usefulness of AAA-IgA in reducing the number of duodenal biopsies in patients with moderate anti-TG2 levels.http://dx.doi.org/10.1155/2013/630463 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Enrico Schirru Fabrice Danjou Lucia Cicotto Rossano Rossino Maria Doloretta Macis Rosanna Lampis Rita-Désirée Jores Mauro Congia |
spellingShingle |
Enrico Schirru Fabrice Danjou Lucia Cicotto Rossano Rossino Maria Doloretta Macis Rosanna Lampis Rita-Désirée Jores Mauro Congia Anti-Actin IgA Antibodies Identify Celiac Disease Patients with a Marsh 3 Intestinal Damage among Subjects with Moderate Anti-TG2 Levels BioMed Research International |
author_facet |
Enrico Schirru Fabrice Danjou Lucia Cicotto Rossano Rossino Maria Doloretta Macis Rosanna Lampis Rita-Désirée Jores Mauro Congia |
author_sort |
Enrico Schirru |
title |
Anti-Actin IgA Antibodies Identify Celiac Disease Patients with a Marsh 3 Intestinal Damage among Subjects with Moderate Anti-TG2 Levels |
title_short |
Anti-Actin IgA Antibodies Identify Celiac Disease Patients with a Marsh 3 Intestinal Damage among Subjects with Moderate Anti-TG2 Levels |
title_full |
Anti-Actin IgA Antibodies Identify Celiac Disease Patients with a Marsh 3 Intestinal Damage among Subjects with Moderate Anti-TG2 Levels |
title_fullStr |
Anti-Actin IgA Antibodies Identify Celiac Disease Patients with a Marsh 3 Intestinal Damage among Subjects with Moderate Anti-TG2 Levels |
title_full_unstemmed |
Anti-Actin IgA Antibodies Identify Celiac Disease Patients with a Marsh 3 Intestinal Damage among Subjects with Moderate Anti-TG2 Levels |
title_sort |
anti-actin iga antibodies identify celiac disease patients with a marsh 3 intestinal damage among subjects with moderate anti-tg2 levels |
publisher |
Hindawi Limited |
series |
BioMed Research International |
issn |
2314-6133 2314-6141 |
publishDate |
2013-01-01 |
description |
A new diagnostic tool (algorithm-1) for coeliac disease (CD) permitting the diagnosis without performing the duodenal biopsy has been recently proposed by the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). It combines symptoms associated with CD, high anti-transglutaminase type 2 antibody (anti-TG2) levels, anti-endomysium-IgA antibodies (EMA), and at-risk HLA. Our aims were (i) to evaluate retrospectively in 227 individuals (149 CD patients and 78 controls) the algorithm-1, (ii) to reduce the number of duodenal biopsies among CD patients for whom algorithm-1 is not applicable through the addition of antiactin IgA antibodies (AAA-IgA), and (iii) to evaluate prospectively algorithm-1 and AAA-IgA in 50 patients with suspected CD. Algorithm-1 identified 70 out of 149 CD patients with Marsh 3 lesions. Adding AAA-IgA to the remaining patients with anti-TG2 levels comprised between 4 and 10 times upper limit of normal (ULN) allowed the detection of further 20 patients with a Marsh 3 damage. In our prospective study, algorithm-1 identified 23 out of 50 patients, whilst further 7 were recognized adding AAA-IgA. We confirm that algorithm-1 may avoid the duodenal biopsy in many CD patients and underscores the usefulness of AAA-IgA in reducing the number of duodenal biopsies in patients with moderate anti-TG2 levels. |
url |
http://dx.doi.org/10.1155/2013/630463 |
work_keys_str_mv |
AT enricoschirru antiactinigaantibodiesidentifyceliacdiseasepatientswithamarsh3intestinaldamageamongsubjectswithmoderateantitg2levels AT fabricedanjou antiactinigaantibodiesidentifyceliacdiseasepatientswithamarsh3intestinaldamageamongsubjectswithmoderateantitg2levels AT luciacicotto antiactinigaantibodiesidentifyceliacdiseasepatientswithamarsh3intestinaldamageamongsubjectswithmoderateantitg2levels AT rossanorossino antiactinigaantibodiesidentifyceliacdiseasepatientswithamarsh3intestinaldamageamongsubjectswithmoderateantitg2levels AT mariadolorettamacis antiactinigaantibodiesidentifyceliacdiseasepatientswithamarsh3intestinaldamageamongsubjectswithmoderateantitg2levels AT rosannalampis antiactinigaantibodiesidentifyceliacdiseasepatientswithamarsh3intestinaldamageamongsubjectswithmoderateantitg2levels AT ritadesireejores antiactinigaantibodiesidentifyceliacdiseasepatientswithamarsh3intestinaldamageamongsubjectswithmoderateantitg2levels AT maurocongia antiactinigaantibodiesidentifyceliacdiseasepatientswithamarsh3intestinaldamageamongsubjectswithmoderateantitg2levels |
_version_ |
1725187895963156480 |